High-Risk Marketing Violations Draw Scrutiny

Much has been made of the decline in FDA warning and untitled letters citing pharma companies for violating marketing and communications requirements and policies. It may be that marketers are being more careful to avoid serious violations, observe some experts. But the change may be due moreOriginal Article